Modifi Biosciences, Inc., a leader in the development of direct DNA modification enabled cancer therapeutics, has been ...

The company will use the funds to advance its pipeline of cancer-targeting preclinical candidates to the “clinic-ready” stage ...

Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...

MSD has acquired US cancer therapeutics developer Modifi Biosciences, a Yale University spinout, enhancing its portfolio with ...

Current health news covers Roche's opposition to Catalent's takeover, cost analysis of weight-loss drugs like Wegovy, U.S.

In a report released today, Carter Gould from Barclays maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...

Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair ...

The acquisition strengthens Merck's oncology portfolio as the company looks to off the expiration of the patent for ...

US pharma multinational Merck has acquired Modifi Biosciences, a developer of new oncology drug molecules, for $30 million ...

Modifi Biosciences announced that it has been acquired by global pharmaceutical giant Merck, with a $30 million down payment.

Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co (NYSE ...

Modifi Biosciences, a New Haven startup biotech that focuses on developing cancer therapies, has been acquired by ...